MOLN
Molecular Partners·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
Bearish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MOLN
Molecular Partners Ag
A Swiss biotech company that develops engineered protein therapy for Covid-19 and cancer
Biological Technology
11/22/2004
06/16/2021
NASDAQ Stock Exchange
159
12-31
Depository Receipts (Ordinary Shares)
Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland
Focus on infectious diseases, oncology and ophthalmology
Molecular Partners AG was incorporated in Switzerland on November 22, 2004. The company is a clinical-stage biopharmaceutical company applying its groundbreaking DARPin product candidates to the treatment of serious diseases, with a current focus on infectious diseases, oncology and ophthalmology. The company's DARPin platform is designed using anchor protein repeats, allowing the company to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially providing patients with products with higher efficacy and fewer adverse events.
Company Financials
EPS
MOLN has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected -0.46094431294393, beating expectations. The chart below visualizes how MOLN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
